144 results on '"Huang, Xu"'
Search Results
2. N-Methyl-d-Aspartate receptor and inflammation in dorsolateral prefrontal cortex in schizophrenia.
- Author
-
Rahman T, Purves-Tyson T, Geddes AE, Huang XF, Newell KA, and Weickert CS
- Subjects
- Cerebral Cortex metabolism, Dorsolateral Prefrontal Cortex, Humans, Inflammation, Prefrontal Cortex diagnostic imaging, Prefrontal Cortex metabolism, Receptors, N-Methyl-D-Aspartate genetics, Receptors, N-Methyl-D-Aspartate metabolism, Schizophrenia diagnostic imaging, Schizophrenia genetics
- Abstract
Lower N-methyl-d-aspartate receptor (NMDAR) GluN1 subunit levels and heightened neuroinflammation are found in the cortex in schizophrenia. Since neuroinflammation can lead to changes in NMDAR function, it is possible that these observations are linked in schizophrenia. We aimed to extend our previous studies by measuring molecular indices of NMDARs that define key functional properties of this receptor - particularly the ratio of GluN2A and GluN2B subunits - in dorsolateral prefrontal cortex (DLPFC) from schizophrenia and control cases (37/37). We sought to test whether changes in these measures are specific to the subset of schizophrenia cases with high levels of inflammation-related mRNAs, defined as a high inflammatory subgroup. Quantitative autoradiography was used to detect 'functional' NMDARs ([
3 H]MK-801), GluN1-coupled-GluN2A subunits ([3 H]CGP-39653), and GluN1-coupled-GluN2B subunits ([3 H]Ifenprodil). Quantitative RT-PCR was used to measure NMDAR subunit transcripts (GRIN1, GRIN2A and GRIN2B). The ratios of GluN2A:GluN2B binding and GRIN2A:GRIN2B mRNAs were calculated as an index of putative NMDAR composition. We found: 1) GluN2A binding, and 2) the ratios of GluN2A:GluN2B binding and GRIN2A:GRIN2B mRNAs were lower in schizophrenia cases versus controls (p < 0.05), and 3) lower GluN2A:GluN2B binding and GRIN2A:GRIN2B mRNA ratios were exaggerated in the high inflammation/schizophrenia subgroup compared to the low inflammation/control subgroup (p < 0.05). No other NMDAR-related indices were significantly changed in the high inflammation/schizophrenia subgroup. This suggests that neuroinflammation may alter NMDAR stoichiometry rather than targeting total NMDAR levels overall, and future studies could aim to determine if anti-inflammatory treatment can alleviate this aspect of NMDAR-related pathology., (Copyright © 2021. Published by Elsevier B.V.)- Published
- 2022
- Full Text
- View/download PDF
3. Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.
- Author
-
Li WT, Huang XF, Deng C, Zhang BH, Qian K, He M, and Sun TL
- Subjects
- Animals, Apoptosis drug effects, Disease Models, Animal, Endoplasmic Reticulum Stress drug effects, Gene Expression Regulation drug effects, Humans, I-kappa B Kinase genetics, Immunity drug effects, Immunity genetics, Inflammation chemically induced, Inflammation genetics, Inflammation pathology, Interleukin-1beta genetics, Interleukin-6 genetics, Nitric Oxide Synthase Type II genetics, Oxidative Stress drug effects, Prefrontal Cortex drug effects, Prefrontal Cortex pathology, Rats, Schizophrenia complications, Schizophrenia genetics, Schizophrenia pathology, Signal Transduction drug effects, Toll-Like Receptor 2 genetics, Endoplasmic Reticulum Stress genetics, Inflammation metabolism, Olanzapine pharmacology, Prefrontal Cortex metabolism, Schizophrenia drug therapy
- Abstract
Objective: Antipsychotics, in particular olanzapine, are first-line medications for schizophrenia. The prefrontal cortex (PFC) is an important region for antipsychotics' therapeutic effects. The PFC inflammatory and immune pathways are associated with schizophrenia pathogenesis. However, the effect of antipsychotics on the inflammatory and immune pathways in the PFC remains unclear. We aimed to examined the time-dependent effect of olanzapine on inflammatory and immune markers in the PFC of rats. Since the inflammatory and immune pathways are related to endoplasmic reticulum (ER) stress, we further investigated whether or not olanzapine-induced inflammation and immune responses were related to ER stress., Methods: Expression of pro-inflammatory markers including IkappaB kinase β (IKKβ), nuclear factor kappa B (NFκB), tumor necrosis factor α (TNF-α), interleukin-6 (IL-6) and IL-1β, and immune-related proteins including inducible nitric oxide synthase (iNOS), toll-like receptor 2 (TLR2) and cluster of differentiation 14 (CD14) were examined by Western blotting., Results: Olanzapine treatments for 1, 8 and 36 days significantly activated the inflammatory IKKβ/NFκB signaling, and increased the expression of TNF-α, IL-6, IL-1β and immune-related proteins such as iNOS, TLR4 and CD14. Olanzapine treatment for 1 day, 8 and 36 days also induced ER stress in the PFC. Co-treatment with an ER stress inhibitor, 4-phenylbutyrate, inhibited olanzapine-induced inflammation and the immune response in the PFC., Conclusion: These results suggested olanzapine exposure could be a factor that induces central inflammation and immunological abnormities in schizophrenia subjects. Olanzapine induces PFC inflammation and immune response, possibly via activating ER stress signaling., (© 2021. Huazhong University of Science and Technology.)
- Published
- 2021
- Full Text
- View/download PDF
4. Decreased serum NCAM is positively correlated with hippocampal volumes and negatively correlated with positive symptoms in first-episode schizophrenia patients.
- Author
-
An H, Qin J, Fan H, Fan F, Tan S, Wang Z, Shi J, Yang F, Tan Y, and Huang XF
- Subjects
- Brain, Hippocampus diagnostic imaging, Humans, Magnetic Resonance Imaging, Neural Cell Adhesion Molecules, Psychotic Disorders, Schizophrenia diagnostic imaging
- Abstract
Background: Neural cell adhesion molecule (NCAM) plays an important role in neurodevelopmental processes and regulates hippocampal plasticity. This study investigated the relationship between the serum NCAM concentrations and hippocampal volume and psychotic symptoms in first-episode drug naïve schizophrenia (FES) patients., Methods: Forty-four FES patients and forty-four healthy controls (HC) were recruited in this study. Serum concentrations of NCAM were measured by ELISA. Psychiatric symptoms were assessed by the positive and negative syndrome scale (PANSS). Brain structural images were obtained using a 3T MRI Scanner and obtained T1 images were processed in order to determine hippocampal grey matter volumes., Results: Schizophrenia patients revealed significantly decreased serum NCAM concentrations (p = 0.017), which were positively correlated with the left (r = 0.523, p < 0.001) and right (r = 0.449, p = 0.041) hippocampal volumes, but negatively correlated with the PANSS positive symptom scores (r = -0.522 p = 0.001). However, no such correlations existed in the HC group., Conclusions: This is the first time to report that decreased serum NCAM concentrations were associated with hippocampal volumes and symptom severity in FES patients. Our data indicate that the low NCAM is possible neuropathology that is associated with the decreased hippocampus in FES patients., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
5. A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: A randomized controlled trial.
- Author
-
Li X, Yuan X, Kang Y, Pang L, Liu Y, Zhu Q, Lv L, Huang XF, and Song X
- Subjects
- Cognition, Double-Blind Method, Humans, Risperidone therapeutic use, Transcranial Magnetic Stimulation, Treatment Outcome, Antipsychotic Agents therapeutic use, Schizophrenia drug therapy
- Abstract
Objective: The present study explored an efficient new therapy that combined repetitive transcranial magnetic stimulation (rTMS) and family intervention in addition to risperidone to improve schizophrenia., Methods: A randomized controlled trial (January 2016-September 2017) involving 200 patients, of which 188 patients completed the 12-week study, and 50 controls were conducted in the research. The patients were randomly assigned to 12 weeks of treatment with risperidone alone (risperidone group), rTMS and risperidone (rTMS group), family intervention and risperidone (family intervention group), rTMS and risperidone plus family intervention (combined group). MATRICS Consensus Cognitive Battery (MCCB) and the Positive and Negative Symptoms Scale (PANSS) were used to evaluate treatment efficacy. Repeated measures analysis of variance (RMANOVA) were performed to evaluate different treatment efficacy between four groups after 12 weeks of treatment., Results: (1) There were no significant differences in sex, age, education, cognitive function, or PANSS scores between the four groups at baseline (p's > 0.05). (2) There was a significant decrease in the PANSS scores and an increase in the MCCB scores after 12 weeks of treatment in all groups (time effect p's < 0.001). (3) The improvements in positive symptoms and negative symptoms were more obvious in the combined group than in other groups (p's < 0.05). (4) The combined group showed the superior effect in cognition function after 12 weeks. (5) And, interestingly, a remarkable synergistic effect between rTMS and family intervention therapy was observed., Conclusion: There was a synergistic effect between rTMS and the family intervention as an effective combined therapy in improving schizophrenia. This study is registered with Chictr.org, number ChiCTR1900024422 (http://www.chictr.org.cn/edit.aspx?pid=34285&htm=4)., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
6. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia.
- Author
-
Osborne AL, Solowij N, Babic I, Lum JS, Newell KA, Huang XF, and Weston-Green K
- Subjects
- Animals, Disease Models, Animal, Female, Hippocampus drug effects, Hippocampus metabolism, Male, Neurons drug effects, Neurons metabolism, Poly I-C, Prefrontal Cortex drug effects, Prefrontal Cortex metabolism, Pregnancy, Rats, Rats, Sprague-Dawley, Cannabidiol pharmacology, Endocannabinoids metabolism, Glutamic Acid metabolism, Schizophrenia metabolism, Signal Transduction drug effects, gamma-Aminobutyric Acid metabolism
- Abstract
The mainstay treatment for schizophrenia is antipsychotic drugs (APDs), which are mostly effective against the positive symptoms (e.g. hallucinations), but provide minimal benefits for the negative symptoms (e.g. social withdrawal) and cognitive deficits. We have recently shown that treatment with the non-intoxicating phytocannabinoid, cannabidiol (CBD), can improve cognition and social interaction deficits in a maternal immune activation (MIA) model relevant to the aetiology of schizophrenia, however, the mechanisms underlying this effect are unknown. An imbalance in the main excitatory (glutamate) and inhibitory (GABA) neurotransmitter systems in the brain plays a role in the pathophysiology of schizophrenia. Therefore, the endocannabinoid system could represent a therapeutic target for schizophrenia as a regulator of glutamate and GABA release via the CB1 receptor (CB1R). This study investigated the effects of chronic CBD treatment on markers of glutamatergic, GABAergic and endocannabinoid signalling in brain regions implicated in social behaviour and cognitive function, including the prefrontal cortex (PFC) and hippocampus (HPC). Time-mated pregnant Sprague-Dawley rats (n = 16) were administered poly I:C (4 mg/kg, i.v.) or saline (control) on gestational day 15. Male offspring were injected with CBD (10 mg/kg, i.p.) or vehicle twice daily from postnatal day 56 for 3 weeks. The prefrontal cortex (PFC) and hippocampus (HPC) were collected for post-mortem receptor binding and Western blot analyses (n = 8 per group). CBD treatment attenuated poly I:C-induced deficits in cannabinoid CB1 receptor binding in the PFC and glutamate decarboxylase 67, the enzyme that converts glutamate to GABA, in the HPC. CBD treatment increased parvalbumin levels in the HPC, regardless of whether offspring were exposed to poly I:C in utero. Conversely, CBD did not affect N-methyl-d-aspartate receptor and gamma-aminobutyric acid (GABA) A receptor binding or protein levels of fatty acid amide hydrolase, the enzyme that degrades the endocannabinoid, anandamide. Overall, these findings show that CBD can restore cannabinoid/GABAergic signalling deficits in regions of the brain implicated in schizophrenia pathophysiology following maternal poly I:C exposure. These findings provide novel evidence for the potential mechanisms underlying the therapeutic effects of CBD treatment in the poly I:C model., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
7. Increased translocator protein (TSPO) binding throughout neurodevelopment in the perinatal phencyclidine rodent model of schizophrenia.
- Author
-
Lum JS, du Bois TM, Mattner F, Katsifis A, Brown SJ, Huang XF, and Newell KA
- Subjects
- Animals, Brain growth & development, Disease Models, Animal, Male, Phencyclidine pharmacology, Protein Binding, Rats, Rats, Sprague-Dawley, Schizophrenia chemically induced, Brain metabolism, Carrier Proteins metabolism, Excitatory Amino Acid Antagonists pharmacology, Receptors, GABA-A metabolism, Schizophrenia metabolism
- Published
- 2019
- Full Text
- View/download PDF
8. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
- Author
-
Osborne AL, Solowij N, Babic I, Lum JS, Huang XF, Newell KA, and Weston-Green K
- Subjects
- Animals, Antipsychotic Agents immunology, Antipsychotic Agents pharmacology, Behavior, Animal physiology, Brain metabolism, Cannabidiol metabolism, Cognition drug effects, Cognitive Dysfunction immunology, Cognitive Dysfunction metabolism, Female, Hippocampus metabolism, Memory, Short-Term drug effects, Neurodevelopmental Disorders immunology, Neurodevelopmental Disorders metabolism, Poly I-C pharmacology, Prefrontal Cortex metabolism, Pregnancy, Prenatal Exposure Delayed Effects immunology, Rats, Rats, Sprague-Dawley, Receptors, N-Methyl-D-Aspartate metabolism, Recognition, Psychology drug effects, Schizophrenia immunology, Cannabidiol immunology, Cannabidiol pharmacology, Schizophrenia metabolism
- Abstract
Cognitive impairment is a major source of disability in schizophrenia and current antipsychotic drugs (APDs) have minimal efficacy for this symptom domain. Cannabidiol (CBD), the major non-intoxicating component of Cannabis sativa L., exhibits antipsychotic and neuroprotective properties. We recently reported the effects of CBD on cognition in male offspring of a maternal immune activation (polyinosinic-polycytidilic acid (poly I:C)) model relevant to the aetiology of schizophrenia; however, the effects of CBD treatment in females are unknown. Sex differences are observed in the onset of schizophrenia symptoms and response to APD treatment. Furthermore, the endogenous cannabinoid system, a direct target of CBD, is sexually dimorphic in humans and rodents. Therefore, the present work aimed to assess the therapeutic impact of CBD treatment on behaviour and neurochemical signalling markers in female poly I:C offspring. Time-mated pregnant Sprague-Dawley rats (n = 16) were administered poly I:C (4 mg/kg; i.v.) or saline (control) on gestational day 15. From postnatal day 56, female offspring received CBD (10 mg/kg, i.p.) or vehicle treatment for approximately 3 weeks. Following 2 weeks of CBD treatment, offspring underwent behavioural testing, including the novel object recognition, rewarded alternation T-maze and social interaction tests to assess recognition memory, working memory and sociability, respectively. After 3 weeks of CBD treatment, the prefrontal cortex (PFC) and hippocampus (HPC) were collected to assess effects on endocannabinoid, glutamatergic and gamma-aminobutyric acid (GABA) signalling markers. CBD attenuated poly I:C-induced deficits in recognition memory, social interaction and glutamatergic N-methyl-d-aspartate receptor (NMDAR) binding in the PFC of poly I:C offspring. Working memory performance was similar between treatment groups. CBD also increased glutamate decarboxylase 67, the rate-limiting enzyme that converts glutamate to GABA, and parvalbumin protein levels in the HPC. In contrast to the CBD treatment effects observed in poly I:C offspring, CBD administration to control rats reduced social interaction, cannabinoid CB1 receptor and NMDAR binding density in the PFC, suggesting that CBD administration to healthy rats may have negative consequences on social behaviour and brain maturation in adulthood. Overall, the findings of this study support the therapeutic benefits of CBD on recognition memory and sociability in female poly I:C offspring, and provide insight into the neurochemical changes that may underlie the therapeutic benefits of CBD in the poly I:C model., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
9. The gut microbiota promotes the pathogenesis of schizophrenia via multiple pathways.
- Author
-
Yuan X, Kang Y, Zhuo C, Huang XF, and Song X
- Subjects
- Animals, Brain immunology, Brain physiopathology, Gastrointestinal Microbiome immunology, Humans, Models, Biological, Neuroimmunomodulation, Schizophrenia immunology, Schizophrenia microbiology, Vagus Nerve physiopathology, Gastrointestinal Microbiome physiology, Schizophrenia etiology
- Abstract
Schizophrenia is a severe mental disorder with unknown etiology. Many mechanisms, including dysregulation of neurotransmitters, immune disturbance, and abnormal neurodevelopment, are proposed for the pathogenesis of schizophrenia. The significance of communication between intestinal flora and the central nervous system through the gut-brain axis is increasingly being recognized. The intestinal microbiota plays an important role in regulating neurotransmission, immune homeostasis, and brain development. We hypothesize that an imbalance in intestinal flora causes immune activation and dysfunction in the gut-brain axis, contributing to schizophrenia. In this review, we examine recent studies that explore the intestinal flora and immune-mediated neurodevelopment of schizophrenia. We conclude that an imbalance in intestinal flora may reduce protectants and increase neurotoxin and inflammatory mediators, causing neuronal and synaptic damage, which induces schizophrenia., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
10. Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment.
- Author
-
Huang XF and Song X
- Subjects
- Animals, Antipsychotic Agents pharmacology, Humans, Models, Biological, Neurites drug effects, Receptors, Cell Surface metabolism, Synapses drug effects, Synapses metabolism, Antipsychotic Agents therapeutic use, Neurites metabolism, Schizophrenia drug therapy
- Abstract
Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly, adolescents and even children. Today, about 1.2% of the worldwide population suffers from psychosis and related disorders, which translates to about 7.5 million subjects potentially targeted by antipsychotic drugs. Neurites project from the cell body of neurons and connect neurons to each other to form neural networks. Deficits in neurite outgrowth and integrity are implicated in psychiatric diseases including schizophrenia. Neurite deficits contribute to altered brain development, neural networking and connectivity as well as symptoms including psychosis and altered cognitive function. This review revealed that (1) antipsychotic drugs could have profound effects on neurites, synaptic spines and synapse, by which they may influence and regulate neural networking and plasticity; (2) antipsychotic drugs target not only neurotransmitter receptors but also intracellular signaling molecules regulating the signaling pathways responsible for neurite outgrowth and maintenance; (3) high doses and chronic administration of antipsychotic drugs may cause some loss of neurites, synaptic spines, or synapsis in the cortical structures. In addition, confounding effects causing neurite deficits may include elevated inflammatory cytokines and antipsychotic drug-induced metabolic side effects in patients on chronic antipsychotic therapy. Unraveling how antipsychotic drugs affect neurites and neural connectivity is essential for improving therapeutic outcomes and preventing aversive effects for patients on antipsychotic drug treatment., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
11. Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients.
- Author
-
An H, Du X, Huang X, Qi L, Jia Q, Yin G, Xiao C, Huang XF, Ning Y, Cassidy RM, Wang L, Soares JC, and Zhang XY
- Subjects
- Body Mass Index, Cross-Sectional Studies, Female, Humans, Male, Malondialdehyde blood, Middle Aged, Schizophrenia complications, Schizophrenia drug therapy, Antipsychotic Agents adverse effects, Obesity chemically induced, Obesity metabolism, Oxidative Stress, Schizophrenia metabolism
- Abstract
Antipsychotic pharmacotherapy is strongly obesogenic and is associated with increased oxidative stress in patients with schizophrenia. However, whether these changes reflect psychopathology, antipsychotic efficacy, or some other factor is not known. Our study aims to investigate the degree of oxidative stress in different BMI categories and to identify clinical symptomatology that may be paired with increased oxidative stress in a schizophrenia population. To this end, we performed a cross-sectional study and recruited 89 long-term inpatients with schizophrenia and collected the following variables: plasma malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), routine biochemical analysis, and psychopathology through the Positive and Negative Syndrome Scale (PANSS). The results indicate that the levels of the lipid peroxidation product, MDA, were significantly higher in the high BMI group than the low (normal) BMI group. As expected, high BMI was associated with an atherogenic lipid profile; however, it was also associated with fewer psychopathological symptoms. Multiple regression analysis found that MDA levels, the PANSS general psychopathology subscore, and triglyceride levels (all p < 0.05) were independent contributors to the BMI in patients. These results suggested that oxidative stress may play an important role in antipsychotic-induced weight gain. Further investigations using the longitudinal design in first-episode schizophrenia patients are needed to explore the beneficial effect of antioxidants on the abnormal lipid metabolism mediated by antipsychotic treatment.
- Published
- 2018
- Full Text
- View/download PDF
12. Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia.
- Author
-
Yuan X, Zhang P, Wang Y, Liu Y, Li X, Kumar BU, Hei G, Lv L, Huang XF, Fan X, and Song X
- Subjects
- Adult, Biomarkers blood, Body Weight drug effects, Feces microbiology, Female, Humans, Male, Schizophrenia microbiology, Treatment Outcome, Young Adult, Antipsychotic Agents therapeutic use, Gastrointestinal Microbiome drug effects, Risperidone therapeutic use, Schizophrenia drug therapy, Schizophrenia metabolism
- Abstract
Objective: This study was to examine the alterations in metabolic parameters, anti-oxidant superoxide dismutase (SOD), inflammatory marker high-sensitivity C-reactive protein (hs-CRP) and microbiota after 24-week risperidone treatment in drug naïve, normal weight, first episode schizophrenia patients; the study further examined the relationship between metabolic changes and changes in microbiota., Methods: Forty-one patients completed the 24-week study and 41 controls were enrolled in this study. Metabolic parameters, SOD, hs-CRP and the copy numbers of 5 fecal bacteria were measured at baseline (both groups) and at different time points (patients only)., Results: Patients had significantly lower numbers of fecal Bifidobacterium spp., Escherichia coli, Lactobacillus spp. compared with healthy controls (HC) (ps < 0.001); in contrast, the numbers of fecal Clostridium coccoides group were significantly higher in the patient group compared with HC (p < 0.001). After 24-week risperidone treatment, there were significant increases in body weight, BMI, fasting blood-glucose, triglycerides, LDL, hs-CRP, SOD and HOMA-IR (p < 0.001), significant increases in the numbers of fecal Bifidobacterium spp. and E. coli (ps < 0.001), and significant decreases in the numbers of fecal Clostridium coccoides group and Lactobacillus spp. (ps < 0.001). Hierarchical multiple linear regression analysis shows that after controlling for potential confounding variables, only the changes in fecal Bifidobacterium spp., among 4 types of fecal bacteria, entered into the model and significantly correlated with the changes in weight (unstandardized coefficient B = 4.413, R
2 change = 0.167, p = 0.009) and BMI (B = 1.639, R2 change = 0.172, p = 0.008) after 24-week treatment., Conclusion: Drug naïve, first episode schizophrenia patients show abnormalities in microbiota composition. Risperidone treatment causes significant changes in certain fecal bacteria, which are likely associated with antipsychotic medication induced metabolic changes., (Copyright © 2018. Published by Elsevier B.V.)- Published
- 2018
- Full Text
- View/download PDF
13. A postmortem analysis of NMDA ionotropic and group 1 metabotropic glutamate receptors in the nucleus accumbens in schizophrenia.
- Author
-
Lum JS, Millard SJ, Huang XF, Ooi L, and Newell KA
- Subjects
- Case-Control Studies, Female, Homer Scaffolding Proteins metabolism, Humans, Male, Middle Aged, Nerve Tissue Proteins metabolism, Nucleus Accumbens metabolism, Receptors, Metabotropic Glutamate biosynthesis, Receptors, N-Methyl-D-Aspartate biosynthesis, Schizophrenia metabolism
- Abstract
Background: The nucleus accumbens (NAcc) has been implicated in the pathology and treatment of schizophrenia. Recent postmortem evidence suggests a hyperglutamatergic state in the NAcc. With the present study we aimed to explore possible glutamatergic alterations in the NAcc of a large schizophrenia cohort., Methods: We performed immunoblots on postmortem NAcc samples from 30 individuals who had schizophrenia and 30 matched controls. We examined the protein expression of primary glutamatergic receptors, including the N -methyl-D-aspartate (NMDA) receptor (NR1, NR2A and NR2B subunits) and the group 1 metabotropic glutamate receptor (mGluR1 and mGluR5; dimeric and monomeric forms). In addition, we measured the group 1 mGluR endogenous regulators, neurochondrin and Homer1b/c, which have recently been implicated in the pathophysiology of schizophrenia., Results: Protein levels of glutamatergic receptors and endogenous regulators were not significantly different between the controls and individuals who had schizophrenia. Furthermore, mGluR5, but not mGluR1, showed a positive association with NMDA receptor subunits, suggesting differential interactions between these receptors in this brain region., Limitations: Investigation of these proteins in antipsychotic-naive individuals, in addition to the subregions of the NAcc and subcellular fractions, will strengthen future studies., Conclusion: The present study does not provide evidence for glutamatergic abnormalities within the NAcc of individuals with schizophrenia. Taken together with the results of previous studies, these findings suggest NMDA receptors and group 1 mGluRs are altered in a brain region-dependent manner in individuals with schizophrenia. The differential associations between mGluR1, mGluR5 and NMDA receptors observed in this study warrant further research into the interactions of these proteins and the implications for the therapeutic and adverse effect profile of glutamatergic-based novel therapeutics.
- Published
- 2018
- Full Text
- View/download PDF
14. Serum NCAM levels and cognitive deficits in first episode schizophrenia patients versus health controls.
- Author
-
An H, Zhou L, Yu Y, Fan H, Fan F, Tan S, Wang Z, Z B, Shi J, Yang F, Zhang X, Tan Y, and Huang XF
- Subjects
- Biomarkers blood, Enzyme-Linked Immunosorbent Assay, Humans, Psychiatric Status Rating Scales, Regression Analysis, Cognition Disorders blood, Cognition Disorders etiology, Neural Cell Adhesion Molecules blood, Schizophrenia blood, Schizophrenia complications, Schizophrenic Psychology
- Abstract
Background: Neural cell adhesion molecule (NCAM) is a glycoprotein and plays an important role in cell-cell adhesion, neural migration, neurite outgrowth, synaptic plasticity and brain development. We investigated the relationship between the serum NCAM concentration and cognitive deficit in first episode drug naïve schizophrenia (FES) patients., Methods: Thirty FES patients and thirty healthy controls were recruited for this study. Psychiatric symptoms were assessed by the positive and negative syndrome scale (PANSS). Cognitive functions were assessed by measurement and treatment research to improve cognition in schizophrenia (MATRICS) and consensus cognitive battery (MCCB). Serum levels of NCAM were determined by ELISA., Results: Schizophrenia patients had decreased serum NCAM concentrations than controls (-30%, p<0.001). Cognitive scores were significantly lower in FES patients than healthy controls (-34%, p<0.001). The NCAM concentrations were positively correlated with the total scores of MCCB (r=0.438, p=0.003). Multiple regression analysis confirmed that serum NCAM concentration was an independent contributor to MCCB total Scores., Conclusions: There were a close relationship between the serum NCAM concentrations and cognitive deficits in FES patients. Since NCAM has an important role in neurodevelopmental processes, these results support the neurodevelopmental dysfunction hypothesis of schizophrenia and suggest that an altered NCAM may be one of the risk factors for schizophrenia including cognitive deficits., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
15. Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients.
- Author
-
Zhang B, Han M, Tan S, De Yang F, Tan Y, Jiang S, Zhang X, and Huang XF
- Subjects
- Adult, Chronic Disease, Consensus, Female, Humans, Male, Middle Aged, Cognition, Schizophrenia physiopathology, Schizophrenic Psychology, Sex Characteristics
- Abstract
Using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), previous study showed significant gender differences for cognitive deficits in immediate and delayed memory in schizophrenia patients. However, RBANS does not include reasoning and problem solving, and social cognition. These cognitive functions can significantly affect the outcomes and daily life in patients. This study examined the gender differences of cognition using the measurement and treatment research to improve cognition in schizophrenia (MATRICS) consensus cognitive battery (MCCB), especially focusing on reasoning and problem solving, and social cognition in schizophrenia patients. The results showed that healthy controls exemplified better cognition than patients in both genders in all examined MCCB scores. Male healthy controls had better reasoning and problem solving and working memory than females, but these gender differences were not presented in schizophrenia patients. Also, male schizophrenia patients showed worse cognition than females on social cognition, processing speed, verbal learning and visual learning. Our results support that male schizophrenia patients had more cognitive impairment than females on reasoning and problem solving, social cognition, processing speed, working memory, verbal learning and visual learning.
- Published
- 2017
- Full Text
- View/download PDF
16. Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies.
- Author
-
Andrews JL, Goodfellow FJ, Matosin N, Snelling MK, Newell KA, Huang XF, and Fernandez-Enright F
- Subjects
- Adult, Aged, Animals, Animals, Newborn, Disease Models, Animal, Excitatory Amino Acid Antagonists toxicity, F-Box Proteins metabolism, Female, Gene Expression Regulation drug effects, Humans, Male, Middle Aged, Phencyclidine toxicity, Postmortem Changes, Protein Inhibitors of Activated STAT metabolism, Proto-Oncogene Proteins c-mdm2 metabolism, Rats, Rats, Sprague-Dawley, Schizophrenia chemically induced, Ubiquitin Thiolesterase metabolism, Ubiquitin-Conjugating Enzymes metabolism, Schizophrenia metabolism, Schizophrenia pathology, Ubiquitins metabolism
- Abstract
Gene expression analyses in post-mortem schizophrenia brains suggest that a number of ubiquitin proteasome system (UPS) genes are associated with schizophrenia; however the status of UPS proteins in the schizophrenia brain is largely unknown. Ubiquitin related proteins are inherently involved in memory, neuronal survival and morphology, which are processes implicated in neurodevelopmental disorders such as schizophrenia. We examined levels of five UPS proteins (Protein Inhibitor of Activated STAT2 [PIAS2], F-Box and Leucine rich repeat protein 21 [FBXL21], Mouse Double Minute 2 homolog [MDM2], Ubiquitin Carboxyl-Terminal Hydrolase-L1 [UCHL1] and Ubiquitin Conjugating Enzyme E2D1 [UBE2D1]) involved in these neuronal processes, within the dorsolateral prefrontal cortex of post-mortem schizophrenia subjects and matched controls (n = 30/group), in addition to across neurodevelopmental time-points (juvenile, adolescent and adult stages of life), utilizing a well-established neurodevelopmental phencyclidine (PCP) animal model of schizophrenia. We observed significant reductions in PIAS2, FBXL21 and MDM2 in schizophrenia subjects compared to controls (p-values ranging from 0.002 to 0.004). In our developmental PCP model, MDM2 protein was significantly reduced in adult PCP-treated rats compared to controls (p = 0.034). Additionally, FBXL21 (p = 0.022) and UCHL1 (p = 0.022) were significantly decreased, whilst UBE2D1 was increased (p = 0.022), in juvenile phencyclidine-treated rats compared to controls. This is the first study reporting alterations of UPS proteins in post-mortem human schizophrenia subjects and in a neurodevelopmental model of schizophrenia. The findings from this study provide strong support for a role of these UPS proteins in the pathology and development of schizophrenia., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
17. Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia.
- Author
-
Hui L, Han M, Yin GZ, Zhang Y, Huang XF, Qian ZK, Gu WG, Gu XC, Zhu XM, Soares JC, Ning Y, Zheng Y, Du XD, and Zhang XY
- Subjects
- Adult, Cognition Disorders etiology, Cognition Disorders genetics, Female, Gene Frequency, Genetic Association Studies, Genotype, Humans, INDEL Mutation, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Schizophrenia genetics, Dopamine beta-Hydroxylase genetics, Polymorphism, Single Nucleotide genetics, Schizophrenia complications, Tardive Dyskinesia etiology, Tardive Dyskinesia genetics
- Abstract
Long-term antipsychotic treatment for schizophrenia is associated with the development of tardive dyskinesia (TD), which is involved in increased cognitive impairment. Dopamine beta-hydroxylase (DBH) gene associated with dopamine and norepinephrine systems influences cognition. Schizophrenia with TD have higher DBH activity than those without TD. This study examined whether DBH5'-insertion/deletion (-Ins/Del) polymorphism could influence cognitive function in schizophrenia with and without TD. The presence of DBH5'-Ins/Del polymorphism was determined in 345 schizophrenia with TD and 397 schizophrenia without TD. The Abnormal Involuntary Movement Scale and Repeatable Battery for Assessment of Neuropsychological Status (RBANS) were used to assess TD severity and cognition. The allele and genotype frequencies of DBH5'-Ins/Del polymorphism did not differ between patients with and without TD (both p>0.05). RBANS total score and subscales did not differ by DBH5'-Ins/Del genotype groups in patients with TD (all p>0.05). However, attention score significantly differed by DBH5'-Ins/Del genotype groups in those without TD (p<0.05). Patients without TD who were Del homozygous had significantly lower attention score than those without TD who were Ins alleles (p<0.05). Immediate memory and attention scores were lower in patients with TD than without TD (both p<0.05). This study indicated that DBH5'-Ins/Del polymorphism may not play a role in the susceptibility to TD and cognitive deficits in schizophrenia with TD, but it may influence cognitive function in schizophrenia with non-TD. Moreover, schizophrenia with TD experienced greater cognitive deficits than those with non-TD, especially in immediate memory and attention., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
18. Neurodevelopmental Expression Profile of Dimeric and Monomeric Group 1 mGluRs: Relevance to Schizophrenia Pathogenesis and Treatment.
- Author
-
Lum JS, Fernandez F, Matosin N, Andrews JL, Huang XF, Ooi L, and Newell KA
- Subjects
- Animals, Female, Male, Phencyclidine pharmacology, Rats, Rats, Sprague-Dawley, Gene Expression Regulation, Developmental, Hippocampus embryology, Neurogenesis, Phencyclidine adverse effects, Prefrontal Cortex embryology, Protein Multimerization, Receptor, Metabotropic Glutamate 5 biosynthesis, Receptors, Metabotropic Glutamate biosynthesis, Schizophrenia chemically induced, Schizophrenia metabolism
- Abstract
Group 1 metabotropic glutamate receptors (mGluR1/mGluR5) play an integral role in neurodevelopment and are implicated in psychiatric disorders, such as schizophrenia. mGluR1 and mGluR5 are expressed as homodimers, which is important for their functionality and pharmacology. We examined the protein expression of dimeric and monomeric mGluR1α and mGluR5 in the prefrontal cortex (PFC) and hippocampus throughout development (juvenile/adolescence/adulthood) and in the perinatal phencyclidine (PCP) model of schizophrenia. Under control conditions, mGluR1α dimer expression increased between juvenile and adolescence (209-328%), while monomeric levels remained consistent. Dimeric mGluR5 was steadily expressed across all time points; monomeric mGluR5 was present in juveniles, dramatically declining at adolescence and adulthood (-97-99%). The mGluR regulators, Homer 1b/c and Norbin, significantly increased with age in the PFC and hippocampus. Perinatal PCP treatment significantly increased juvenile dimeric mGluR5 levels in the PFC and hippocampus (37-50%) but decreased hippocampal mGluR1α (-50-56%). Perinatal PCP treatment also reduced mGluR1α dimer levels in the PFC at adulthood (-31%). These results suggest that Group 1 mGluRs have distinct dimeric and monomeric neurodevelopmental patterns, which may impact their pharmacological profiles at specific ages. Perinatal PCP treatment disrupted the early expression of Group 1 mGluRs which may underlie neurodevelopmental alterations observed in this model.
- Published
- 2016
- Full Text
- View/download PDF
19. Common susceptibility variants are shared between schizophrenia and psoriasis in the Han Chinese population.
- Author
-
Yin X, Wineinger NE, Wang K, Yue W, Norgren N, Wang L, Yao W, Jiang X, Wu B, Cui Y, Shen C, Cheng H, Zhou F, Chen G, Zuo X, Zheng X, Fan X, Wang H, Wang L, Lee J, Lam M, Tai ES, Zhang Z, Huang Q, Sun L, Xu J, Yang S, Wilhelmsen KC, Liu J, Schork NJ, and Zhang X
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Asian People genetics, Case-Control Studies, China ethnology, Cohort Studies, Genome-Wide Association Study, Genotyping Techniques, HLA Antigens genetics, Humans, Middle Aged, Multifactorial Inheritance, Regression Analysis, Singapore, Young Adult, Genetic Predisposition to Disease, Genetic Variation, Psoriasis genetics, Schizophrenia genetics
- Abstract
Background: Previous studies have shown that individuals with schizophrenia have a greater risk for psoriasis than a typical person. This suggests that there might be a shared genetic etiology between the 2 conditions. We aimed to characterize the potential shared genetic susceptibility between schizophrenia and psoriasis using genome-wide marker genotype data., Methods: We obtained genetic data on individuals with psoriasis, schizophrenia and control individuals. We applied a marker-based coheritability estimation procedure, polygenic score analysis, a gene set enrichment test and a least absolute shrinkage and selection operator regression model to estimate the potential shared genetic etiology between the 2 diseases. We validated the results in independent schizophrenia and psoriasis cohorts from Singapore., Results: We included 1139 individuals with psoriasis, 744 with schizophrenia and 1678 controls in our analysis, and we validated the results in independent cohorts, including 441 individuals with psoriasis (and 2420 controls) and 1630 with schizophrenia (and 1860 controls). We estimated that a large fraction of schizophrenia and psoriasis risk could be attributed to common variants ( h
2 SNP = 29% ± 5.0%, p = 2.00 × 10-8 ), with a coheritability estimate between the traits of 21%. We identified 5 variants within the human leukocyte antigen ( HLA ). We discovered that variants contributing most to the shared heritable component between psoriasis and schizophrenia were enriched in antigen processing and cell endoplasmic reticulum.p < 2.00 × 10-16 ). We discovered that variants contributing most to the shared heritable component between psoriasis and schizophrenia were enriched in antigen processing and cell endoplasmic reticulum., Limitations: Our sample size was relatively small. The findings of 5 HLA gene variants were complicated by the complex structure in the HLA region., Conclusion: We found evidence for a shared genetic etiology between schizophrenia and psoriasis. The mechanism for this shared genetic basis likely involves immune and calcium signalling pathways.- Published
- 2016
- Full Text
- View/download PDF
20. Smoking and Serum Lipid Profiles in Schizophrenia.
- Author
-
An HM, Tan YL, Tan SP, Shi J, Wang ZR, Yang FD, Huang XF, Soars JC, Kosten TR, and Zhang XY
- Subjects
- Adult, Aged, Analysis of Variance, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Schizophrenia epidemiology, Smoking epidemiology, Lipids blood, Schizophrenia blood, Schizophrenic Psychology, Smoking blood
- Abstract
Schizophrenia is associated with a high prevalence of cigarette-smoking and abnormal lipid profiles. The purpose of this study was to determine whether the profiles differ between schizophrenic smokers and non-smokers and whether the lipid profiles are related to psychopathological symptoms. Serum lipid profiles were measured in 130 male inpatients with DSM-IV-defined schizophrenia: 104 smokers and 26 non-smokers. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Our results showed that positive PANSS symptoms were fewer in smokers than in non-smokers, while the negative symptoms were fewer in those who smoked more cigarettes. Total protein and globulin levels were significantly lower in the smokers than in the non-smokers. However, there was no significant difference in total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol, apolipoprotein A1, or apolipoprotein B between the smokers and non-smokers. However, the PANSS positive subscale had a significant negative correlation with the HDL-c levels (a protective factor) in the smokers but not in the non-smokers. Our findings suggest that schizophrenic patients who smoke have fewer psychotic symptoms, but contrary to expectation, smoking does not alter lipid profile levels.
- Published
- 2016
- Full Text
- View/download PDF
21. Use of conducting polymers to facilitate neurite branching in schizophrenia-related neuronal development.
- Author
-
Stewart EM, Wu Z, Huang XF, Kapsa RM, and Wallace GG
- Subjects
- Cell Line, Gene Knockout Techniques, Humans, Neuregulin-1 genetics, Schizophrenia genetics, Tissue Scaffolds chemistry, Neurons cytology, Neurons drug effects, Polymers pharmacology, Pyrroles pharmacology, Schizophrenia physiopathology
- Abstract
Schizophrenia (SCZ) is a debilitating mental disorder which results in high healthcare and loss of productivity costs to society. This disease remains poorly understood, however there is increasing evidence suggesting a role for oxidative damage in the disease etiology. We aimed to examine the effect of the conducting polymer polypyrrole on the growth and morphology of both wildtype and neuregulin-1 knock out (NRG-1 +/-) explant cells. Polypyrrole is an organic conducting polymer known to be cytocompatible and capable of acting as a platform for effective stimulation of neurons. Here we demonstrate for the first time the ability of this material to mediate processes occurring in disease affected neurons: schizophrenic model cortical neurons. Prefrontal cortical cells were grown on conducting polymer scaffolds of specific composition and showed significantly increased neurite branching and outgrowth length on the polymers compared to controls. Concurrently, a more significant enhancement was seen in both parameters in the NRG-1 +/- model cells. This finding implies that conducting polymers such as polypyrrole may be utilised to overcome neuro-functional deficits associated with neurological disease in humans.
- Published
- 2016
- Full Text
- View/download PDF
22. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
- Author
-
Engel M, Snikeris P, Matosin N, Newell KA, Huang XF, and Frank E
- Subjects
- Animals, Antipsychotic Agents pharmacology, Benzodiazepines pharmacology, Disease Models, Animal, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Nucleus Accumbens drug effects, Nucleus Accumbens metabolism, Olanzapine, Phencyclidine pharmacology, Prefrontal Cortex drug effects, Prefrontal Cortex metabolism, Protein Binding drug effects, Protein Binding physiology, Receptors, GABA-A metabolism, Receptors, Metabotropic Glutamate metabolism, Receptors, N-Methyl-D-Aspartate metabolism, Amino Acids pharmacology, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Receptors, GABA-A deficiency, Receptors, Metabotropic Glutamate agonists, Receptors, N-Methyl-D-Aspartate deficiency, Schizophrenia metabolism
- Abstract
Rationale: An imbalance of excitatory and inhibitory neurotransmission underlies the glutamate hypothesis of schizophrenia. Agonists of group II metabotropic glutamate receptors, mGluR2/3, have been proposed as novel therapeutic agents to correct this imbalance. However, the influence of mGluR2/3 activity on excitatory and inhibitory neurotransmitter receptors has not been explored., Objectives: We aimed to investigate the ability of a novel mGluR2/3 agonist, LY379268, to modulate the availability of the excitatory N-methyl-D-aspartate receptor (NMDA-R) and the inhibitory gamma-aminobutyrate-A receptor (GABAA-R), in a two-hit mouse model of schizophrenia., Methods: Wild type (WT) and heterozygous neuregulin 1 transmembrane domain mutant mice (NRG1 HET) were treated daily with phencyclidine (10 mg/kg ip) or saline for 14 days. After a 14-day washout, an acute dose of the mGluR2/3 agonist LY379268 (3 mg/kg), olanzapine (antipsychotic drug comparison, 1.5 mg/kg), or saline was administered. NMDA-R and GABAA-R binding densities were examined by receptor autoradiography in several schizophrenia-relevant brain regions., Results: In both WT and NRG1 HET mice, phencyclidine treatment significantly reduced NMDA-R and GABAA-R binding density in the prefrontal cortex, hippocampus, and nucleus accumbens. Acute treatment with LY379268 restored NMDA-R and GABAA-R levels in the two-hit mouse model comparable to olanzapine., Conclusions: We demonstrate that the mGluR2/3 agonist LY379268 restores excitatory and inhibitory deficits with similar efficiency as olanzapine in our two-hit schizophrenia mouse model. This study significantly contributes to our understanding of the mechanisms underlying the therapeutic effects of LY379268 and supports the use of agents aimed at mGluR2/3.
- Published
- 2016
- Full Text
- View/download PDF
23. Association between DβH 5'-insertion/deletion polymorphism and cognition in patients with chronic schizophrenia.
- Author
-
Hui L, Han M, Huang XF, Ye MJ, Zhang X, He JC, Lv MH, Soares JC, and Zhang XY
- Subjects
- Adult, Aged, Case-Control Studies, Chronic Disease, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Schizophrenic Psychology, Young Adult, Cognition Disorders complications, Cognition Disorders genetics, Dopamine beta-Hydroxylase genetics, INDEL Mutation genetics, Polymorphism, Genetic genetics, Schizophrenia complications, Schizophrenia genetics
- Abstract
Background: Cognitive deficits have been identified as a core feature of patients with schizophrenia. Many genes associated with the dopamine and norepinephrine systems are related to the cognitive deficits of patients with schizophrenia. Dopamine β-hydroxylase (DβH) is a key enzyme that converts dopamine to norepinephrine and for which activity and levels are under strong genetic control., Objective: To examine whether the DβH 5'-insertion/deletion (Ins/Del) polymorphism influences cognitive function in patients with chronic schizophrenia., Method: The presence of the DβH 5'-Ins/Del polymorphism was determined in 733 patients with chronic schizophrenia (diagnosed according to DSM-IV) and 544 healthy controls using a case-control design. We assessed all of the patients' psychopathology using the Positive and Negative Syndrome Scale (PANSS) and cognition in 540 patients with chronic schizophrenia and 297 healthy controls using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). This study was conducted between 2008 and 2011., Results: The allelic and genotypic frequencies of the DβH 5'-Ins/Del polymorphism were not significantly different between patients with schizophrenia and healthy controls (both P values > .05). However, the cognitive test scores were significantly lower in patients than in the healthy controls for all scales (all P values < .05), except visuospatial/constructional (P > .05). The attention score significantly differed according to the genotypic group (P < .05) in patients but not in the healthy controls (P > .05). In patients with chronic schizophrenia, the mean ± SD attention score was lower in the DβH 5'-Del/Del genotype (65.7 ± 16.8) than in the DβH 5'-Ins/Del genotype (71.4 ± 18.0; P = .007) and the DβH 5'-Ins/Ins genotype (70.8 ± 17.1; P = .02)., Conclusions: This study found that patients with chronic schizophrenia had poorer cognitive function than the healthy controls in all examined cognitive domains except for visuospatial/constructional. No significant association was found between the DβH 5'-Ins/Del polymorphism and patients with chronic schizophrenia. However, the DβH 5'-Del/Del genotype may be specific to attentional decrements in patients with chronic schizophrenia., (© Copyright 2016 Physicians Postgraduate Press, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
24. Interaction of BDNF with cytokines in chronic schizophrenia.
- Author
-
Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Wu HE, Zunta-Soares GB, Huang XF, Kosten TR, and Soares JC
- Subjects
- Adult, Antipsychotic Agents therapeutic use, Female, Humans, Interleukin-2 blood, Interleukin-6 blood, Interleukin-8 blood, Male, Middle Aged, Schizophrenia complications, Schizophrenia drug therapy, Tumor Necrosis Factor-alpha blood, Brain-Derived Neurotrophic Factor blood, Cytokines blood, Schizophrenia blood
- Abstract
Brain-derived neurotrophic factor (BDNF) interacts with cytokines. Although both BDNF and cytokines occur at abnormal levels in schizophrenia patients, their interactions have not yet been examined. We therefore compared serum BDNF, TNF-α, interleukin (IL)-2, IL-6, and IL-8 levels in 92 chronically medicated schizophrenia patients and 60 healthy controls. We correlated these serum levels within these subject groups with each other and with clinical symptoms assessed according to the Positive and Negative Syndrome Scale (PANSS). Compared to the control group, the schizophrenia patients had significantly lower BDNF and TNF-α levels, and higher IL-2, IL-6, and IL-8 levels. The patients also showed a significant positive correlation between BDNF and both IL-2 and IL-8 levels, and low BDNF and TNF-α levels together were associated with poor performance on the PANSS cognitive factor. Thus, an interaction between cytokines and neurotrophic factors may be implicated in the pathophysiology of chronic schizophrenia. In particular, the cytokine TNF-α may interact with BNDF causing cognitive impairment., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
25. Glucose disturbances in first-episode drug-naïve schizophrenia: Relationship to psychopathology.
- Author
-
Zhang XY, Chen DC, Tan YL, An HM, Zunta-Soares GB, Huang XF, and Soares JC
- Subjects
- Adult, Female, Humans, Insulin blood, Lipids blood, Male, Young Adult, Blood Glucose metabolism, Insulin Resistance physiology, Schizophrenia blood
- Abstract
Accumulating evidence shows abnormal glucose metabolism in schizophrenia, even at the onset of psychosis. This study aims to examine the glucose and lipid metabolism in first-episode and drug naïve (FEDN) patients with schizophrenia and to explore their relationships with psychopathology, which have been under-investigated. Fasting glucose and lipid profiles, as well as homeostasis model of assessment-insulin resistance (HOMA-IR) index were determined in 120 never-medicated first-episode and 31 healthy control subjects matched for gender and age. The schizophrenia symptomatology was assessed by the positive and negative syndrome scale (PANSS). Our results showed that schizophrenia patients had a significantly higher level of fasting plasma glucose (p<0.0001) and insulin (p=0.038). HOMA, an indicator of insulin resistance was higher in the patients than in the healthy controls (p=0.008). No differences were found between the patients and healthy subjects in the levels of plasma triglycerides, high-density lipoprotein, and low-density lipoprotein, except that the cholesterol level was higher in the patients than health subjects (p=0.016). A significant negative association between plasma glucose levels and the PANSS positive symptom subscores was observed (p=0.013). Stepwise multiple regression analysis identified insulin resistance, insulin and the PANSS positive symptom subscore as significant predictor factors for glucose level. These results suggest that abnormal glucose metabolism may be associated with the pathogenesis and psychopathology of schizophrenia in the early phases of the disease process., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
26. Gender differences in cognitive deficits in schizophrenia with and without diabetes.
- Author
-
Zhang BH, Han M, Zhang XY, Hui L, Jiang SR, Yang FD, Tan YL, Wang ZR, Li J, and Huang XF
- Subjects
- Adult, Aged, Cognition Disorders blood, Cognition Disorders epidemiology, Cross-Sectional Studies, Diabetes Mellitus blood, Diabetes Mellitus epidemiology, Female, Glycated Hemoglobin metabolism, Humans, Male, Middle Aged, Neuropsychological Tests, Schizophrenia blood, Schizophrenia epidemiology, Schizophrenic Psychology, Cognition Disorders diagnosis, Diabetes Mellitus diagnosis, Schizophrenia diagnosis, Sex Characteristics
- Abstract
This study investigated gender differences in cognition in schizophrenia with and without diabetes. Cognition was assessed in 263 individuals with schizophrenia with age range (40-68): 67 males and 34 females with schizophrenia with diabetes; and 125 males and 37 females with schizophrenia without diabetes according to the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Fasting glucose, hemoglobin A1c (HbA1c) and lipid levels were measured. Results showed that male individuals performed worse on most cognitive tasks, especially attention, in schizophrenia with than without diabetes. This result was not observed in female individuals. Also, individuals of both genders showed higher fasting glucose and HbA1c in schizophrenia with than without diabetes. In schizophrenia with diabetes, males had significantly worse cognition than females in all cognitive domains. Higher HbA1c, lower high-density lipoprotein, and an earlier age of onset of schizophrenia were found in males compared with female individuals. HbA1c was negatively associated with attention and the RBANS total score for males but not for females. In schizophrenia without diabetes, males showed worse performance in immediate and delayed memory than females. This study support cognition was worse for males with schizophrenia irrespective of whether they have diabetes. However, diabetes exemplified the gender differences, especially in attention., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
27. Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.
- Author
-
Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, and Newell KA
- Subjects
- Animals, Antipsychotic Agents pharmacology, Antipsychotic Agents therapeutic use, Benzodiazepines pharmacology, Benzodiazepines therapeutic use, CA1 Region, Hippocampal drug effects, Chlorpromazine therapeutic use, Dimerization, Female, Haloperidol pharmacology, Haloperidol therapeutic use, Humans, Immunoblotting, Male, Middle Aged, Neuropeptides metabolism, Olanzapine, Rats, Sprague-Dawley, Schizophrenia drug therapy, CA1 Region, Hippocampal metabolism, Carrier Proteins metabolism, Membrane Proteins metabolism, Nerve Tissue Proteins metabolism, Receptor, Metabotropic Glutamate 5 metabolism, Schizophrenia metabolism
- Abstract
Metabotropic glutamate receptor 5 (mGluR5) is involved in hippocampal-dependent learning and memory, which are processes disrupted in schizophrenia. Recent evidence from human genetic and animal studies suggests that the regulation of mGluR5, including its interaction with trafficking molecules, may be altered in the disorder. However there have been no investigations of hippocampal mGluR5 or mGluR5 trafficking molecules in the postmortem schizophrenia brain to confirm this. In the present study, we investigated whether protein expression of mGluR5, as well as Norbin and Tamalin (modulators of mGluR5 signalling and trafficking), might be altered in the schizophrenia brain, using postmortem samples from the hippocampal CA1 region of schizophrenia subjects and matched controls (n=20/group). Protein levels of mGluR5 (total: 42%, p<0.001; monomer: 25%, p=0.011; dimer: 52%, p<0.001) and mGluR5 trafficking molecules (Norbin: 47%, p<0.001; Tamalin: 34%, p=0.009) were significantly higher in schizophrenia subjects compared to controls. To determine any influence of antipsychotic drug treatment, all proteins were also correlated with lifetime chlorpromazine equivalents in patients, and separately measured in the hippocampus of rats exposed to haloperidol or olanzapine treatment. mGluR5 was negatively correlated with lifetime antipsychotic drug exposure in schizophrenia patients, suggesting antipsychotic drugs could reduce mGluR5 protein in schizophrenia subjects. In contrast, mGluR5 and mGluR5 trafficking molecules were not altered in the hippocampus of antipsychotic drug treated rats. This investigation provides strong support for the hypothesis that mGluR5 is involved in the pathology of schizophrenia, and that alterations to mGluR5 trafficking might contribute to the hippocampal-dependent cognitive dysfunctions associated with this disorder., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
28. Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation.
- Author
-
Matosin N, Fernandez-Enright F, Fung SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, and Newell KA
- Subjects
- Adolescent, Adult, Aged, Animals, Antipsychotic Agents pharmacology, Carrier Proteins metabolism, Cohort Studies, Disease Models, Animal, Female, Humans, Intracellular Signaling Peptides and Proteins metabolism, Male, Membrane Proteins metabolism, Middle Aged, Nerve Tissue Proteins metabolism, Neuropeptides metabolism, Prefrontal Cortex drug effects, RNA, Messenger metabolism, Rats, Sprague-Dawley, Schizophrenia drug therapy, Young Adult, Prefrontal Cortex metabolism, Receptor, Metabotropic Glutamate 5 metabolism, Schizophrenia metabolism
- Abstract
Knockout of genes encoding metabotropic glutamate receptor 5 (mGluR5) or its endogenous regulators, such as Norbin, induce a schizophrenia-like phenotype in rodents, suggesting dysregulation of mGluR5 in schizophrenia. Human genetic and pharmacological animal studies support this hypothesis, but no studies have explored mGluR5 dysfunction at the molecular level in the postmortem schizophrenia brain. We assessed mGluR5 mRNA and protein levels in the dorsolateral prefrontal cortex (DLPFC) using a large cohort of schizophrenia and control subjects (n = 37/group), and additionally measured protein levels of recently discovered mGluR5 endogenous regulators, Norbin (neurochondrin), Tamalin (GRASP-1), and Preso1 (FRMPD4), which regulate mGluR5 localization, internalization and signaling. While mGluR5 mRNA expression was unchanged, mGluR5 protein levels were significantly higher in schizophrenia subjects compared to controls (total: +22%; dimer: +54%; p < 0.001). Conversely, mGluR5 regulatory proteins were expressed at lower levels in schizophrenia subjects compared to controls (Norbin -37%, p < 0.001; Tamalin -30%, p = 0.084; Preso1 -29%, p = 0.001). mGluR5 protein was significantly associated with mGluR5 mRNA and mGluR5 endogenous regulators in control subjects, but these associations were lost in schizophrenia subjects. Lastly, there were no associations between protein measures and lifetime antipsychotic history in schizophrenia subjects. To confirm no antipsychotic influence, all proteins were measured in the prefrontal cortex of rats exposed to haloperidol or olanzapine; there were no effects of antipsychotic drug treatment on mGluR5, Norbin, Tamalin or Preso1. The results from our study provide compelling evidence that mGluR5 regulation is altered in schizophrenia, likely contributing to the altered glutamatergic signaling that is associated with the disorder.
- Published
- 2015
- Full Text
- View/download PDF
29. Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.
- Author
-
Hui L, Han M, Huang XF, Ye MJ, Zheng K, He JC, Lv MH, Zhang BH, Soares JC, and Zhang XY
- Subjects
- Adult, Aged, Antipsychotic Agents therapeutic use, Chronic Disease, Female, Gene Frequency, Genetic Predisposition to Disease, Genotyping Techniques, Humans, Male, Middle Aged, Movement Disorders physiopathology, Multivariate Analysis, Psychiatric Status Rating Scales, Schizophrenia drug therapy, Schizophrenia physiopathology, Severity of Illness Index, Young Adult, Dopamine beta-Hydroxylase genetics, Movement Disorders genetics, Polymorphism, Genetic, Schizophrenia genetics
- Abstract
Overactivity of dopaminergic neurotransmission is a putative mechanism of tardive dyskinesia (TD). Previous studies have found dysfunction in plasma dopamine beta-hydoxylase (DBH) in schizophrenia with TD. Moreover, DBH, whose activity and levels are strongly controlled by the DBH gene, is a key enzyme in the conversion of dopamine (DA) to norepinephrine (NE) associated with excited behavior. This study examined whether the DBH5'-insertion/deletion (Ins/Del) polymorphism was associated with excited behavior in schizophrenia with TD. The presence of the DBH5'-Ins/Del polymorphism was determined in 741 schizophrenia with TD (n = 345) and without TD (n = 396). The Abnormal Involuntary Movement Scale and Positive and Negative Syndrome Scale were used to assess the severity of TD and psychopathology of schizophrenia. There was no significant difference in the allelic and genotypic frequencies of the DBH5'-Ins/Del polymorphism between schizophrenia with and without TD (both p > 0.05). However, the excited symptoms score was significantly different to the DBH5'-Ins/Del genotypic groups in schizophrenia with TD (p < 0.05) but not in the two groups of non-TD and total patients (both p > 0.05). The excited symptoms score was higher in TD patients with the Del/Del genotype than those with Ins alleles (p = 0.015). Our findings suggest that the DBH5'-Ins/Del polymorphism may not contribute directly to the development of TD in schizophrenia, but it may be involved in the excited behavior of TD patients.
- Published
- 2015
- Full Text
- View/download PDF
30. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
- Author
-
Han M, Zhang XY, Chen DC, Tan YL, Song CS, Yu YH, and Huang XF
- Subjects
- Adult, Aged, Antipsychotic Agents administration & dosage, Case-Control Studies, Clozapine administration & dosage, Cognition Disorders complications, Cross-Sectional Studies, Female, Humans, Language, Male, Memory drug effects, Middle Aged, Neuropsychological Tests, Risperidone administration & dosage, Schizophrenia complications, Antipsychotic Agents therapeutic use, Clozapine therapeutic use, Cognition Disorders drug therapy, Risperidone therapeutic use, Schizophrenia drug therapy, Schizophrenic Psychology
- Abstract
Cognitive deficits are a core feature of schizophrenia. There is ongoing debate on whether cognition is affected by antipsychotic drugs (APDs). This study examined the effect of long-term treatment with APDs on cognition in schizophrenia. Cognitive function was assessed in 418 patients with schizophrenia on long-term treatment with APDs (215 on clozapine, 91 on risperidone and 112 on typical APDs) and 159 healthy controls using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Schizophrenia symptomatology was assessed using the Positive and Negative Syndrome Scale (PANSS). We found that cognitive test scores were significantly lower in all patients compared with the healthy controls on almost all of the total and subscores of RBANS (all P<0.001), except for the visuospatial/constructional index. Individuals taking clozapine showed worse immediate and delayed memory performance than those taking typical APDs (all P<0.01). Moreover, individuals taking clozapine showed better language performance than those taking risperidone (P<0.01). Immediate memory and delayed memory were modestly correlated with the types of APDs and the PANSS negative scores. Our results show that individuals taking clozapine performed worse in immediate and delayed memory than those taking typical APDs, but exemplified better language performance than those taking risperidone.
- Published
- 2015
- Full Text
- View/download PDF
31. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia.
- Author
-
An HM, Tan YL, Shi J, Wang ZR, Soars JC, Wu JQ, Yang FD, Huang XF, and Zhang XY
- Subjects
- Adult, Aged, Blood Chemical Analysis, Chronic Disease, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Movement Disorders complications, Psychiatric Status Rating Scales, Regression Analysis, Schizophrenia complications, Severity of Illness Index, Interleukin-2 blood, Interleukin-6 blood, Interleukin-8 blood, Movement Disorders blood, Schizophrenia blood
- Abstract
Immune deregulation has been postulated to be one of the mechanisms underlying the pathogenesis of tardive dyskinesia (TD). We hypothesized that interleukins would have a link with TD in schizophrenia patients. In this study, the serum IL-2, IL-6 and IL-8 levels were examined by enzyme-linked immunosorbent assay (ELISA) in schizophrenia patients with TD (n=48) and without TD (n=45), and healthy controls (n=44). The psychopathological symptoms of schizophrenia were assessed by the Positive and Negative Syndrome Scale (PANSS). The severity of TD was evaluated using Abnormal Involuntary Movement Scale (AIMS). The results showed that serum IL-2, IL-6 and IL-8 levels were significantly different among schizophrenia patients with TD and without TD and normal controls. Moreover, IL-2 level was significantly correlated with PANSS positive subscale and general subscale in patients with TD and without TD. In addition, IL-2 level was positively correlated with AIMS score in TD patients. The results supported that immune disturbance is related to the schizophrenia patients, especially to the patients with TD and ILs might play an important role in the pathophysiology of schizophrenia patients with TD., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
32. Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.
- Author
-
Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J, Huang XF, and Newell KA
- Subjects
- Adult, Aging metabolism, Autoradiography, Cohort Studies, Female, Humans, Male, Middle Aged, Receptor, Metabotropic Glutamate 5 metabolism, Young Adult, Bipolar Disorder metabolism, Depressive Disorder, Major metabolism, Gyrus Cinguli metabolism, Psychotic Disorders metabolism, Receptors, Metabotropic Glutamate metabolism, Schizophrenia metabolism
- Abstract
Background: Metabotropic glutamate receptors 2/3 (mGluR2/3) and 5 (mGluR5) are novel therapeutic targets for major depression (MD), bipolar disorder (BD) and schizophrenia. We aimed to determine whether mGluR2/3 and mGluR5 binding in the anterior cingulate cortex (ACC), a brain region essential for the regulation of mood, cognition and emotion, were differentially altered in these pathologies., Methods: Using postmortem human brains derived from 2 cohorts, [(3)H]LY341495 binding to mGluR2/3 and [(3)H]MPEP binding to mGluR5 were measured by receptor autoradiography in the ACC. The first cohort comprised samples from individuals who had MD with psychosis (MDP), MD without psychosis (MDNP) and matched controls (n = 11-12 per group). The second cohort comprised samples from individuals who had MDNP, BD, schizophrenia and matched controls (n = 15 per group)., Results: No differences in mGluR2/3 or mGluR5 binding were observed in the MDP, MDNP, BD or schizophrenia groups compared with the control group (all p > 0.05). Importantly, there were also no differences in binding densities between the psychiatric disorders (p > 0.05). We did, however, observe age-related effects, with consistent negative associations between mGluR2/3 and age in the control group (r < -0.575, p < 0.025) and the psychotic disorder groups (MDP and schizophrenia: r = -0.765 to -0.515, p < 0.05), but not in the mood disorder groups (MDNP, BD)., Limitations: Replication in larger independent cohorts and medication-naive individuals would strengthen these findings., Conclusion: Our findings suggest that mGluRs are unaltered in the ACC; however, the presence of altered receptor function cannot be discounted and requires further investigation. Taken together with previous studies, which report differential changes in mGluR2, 3 and 5 across these disorders, we suggest mGluRs may be affected in a brain region-specific manner.
- Published
- 2014
- Full Text
- View/download PDF
33. GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia.
- Author
-
Geddes AE, Huang XF, and Newell KA
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Functional Laterality physiology, Hippocampus metabolism, Receptors, N-Methyl-D-Aspartate metabolism, Schizophrenia metabolism
- Abstract
Background: Increasing evidence indicates that alterations to the function and subunit composition of the glutamatergic NMDA receptor are associated with the pathophysiology of schizophrenia. The GluN2B protein is a structural and functional subunit of the NMDA receptor, with a growing body of evidence indicating it plays a critical role in cognitive functions mediated by the NMDA receptor. The hippocampus plays a key role in cognitive function, with studies suggesting lateralised glutamatergic dysfunction in this region may contribute to the cognitive deficits observed in schizophrenia patients. The present study, for the first time, investigated GluN2B protein and binding density in the left and right hippocampus of 20 schizophrenia subjects compared to 20 matched controls., Methods: The dentate gyrus of 20 schizophrenia and 20 control subjects, matched for age, post-mortem interval, and pH, was obtained from the NSW Tissue Resource Centre, Australia. Each group consisted of dentate gyrus from the left hemisphere (n = 10) and right hemisphere (n = 10). GluN2B protein density was measured via immunoblotting. GluN2B binding density was measured using the GluN2B antagonist, [3H] Ifenprodil. Analyses of covariance, covarying for demographic variables that influenced the data, were used to test for statistical significance between schizophrenia and control groups. Pearson's correlations were used to determine the association of GluN2B protein and binding density with demographic and clinical variables, including lifetime antipsychotic drug exposure., Results: GluN2B protein levels were decreased by 43% in the left hemisphere of schizophrenia subjects compared to controls (p = 0.012). There was no difference in GluN2B protein levels in the right hemisphere of schizophrenia subjects compared to controls. There were no differences in [(3)H] Ifenprodil binding according to diagnosis or hemisphere. There were no associations between GluN2B measures and lifetime antipsychotic drug exposure., Conclusions: Our findings provide the first evidence of GluN2 protein abnormalities in the hippocampus in schizophrenia, highlighting the hippocampal lateralisation in this disorder. We suggest this deficit could contribute to the cognitive dysfunctions that arise in patients. These findings provide preliminary support for the development of therapeutics that target the GluN2B subunit, as a novel therapy for schizophrenia, especially the cognitive dysfunctions.
- Published
- 2014
- Full Text
- View/download PDF
34. In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.
- Author
-
Jafari S, Huang XF, Andrews JL, and Fernandez-Enright F
- Subjects
- Animals, Antipsychotic Agents administration & dosage, Benzodiazepines administration & dosage, Female, Olanzapine, Rats, Rats, Sprague-Dawley, Antipsychotic Agents therapeutic use, Benzodiazepines therapeutic use, Schizophrenia drug therapy
- Abstract
Olanzapine (Olz) is one of the most effective antipsychotic drugs commonly used for treating schizophrenia. Unfortunately, Olz administration is associated with severe weight gain and metabolic disturbances. Both patients and clinicians are highly interested in the development of new antipsychotics which are as effective as atypical antipsychotics but which have a lower propensity to induce metabolic side effects. In the present study, we examined two new derivatives of Olz; OlzEt (2-ethyl-4-(4'-methylpiperazin-1'-yl)-10Hbenzo[b]thieno[2,3-e][1,4]diazepine), and OlzHomo (2-ethyl-4-(4'-methyl-1',4'-diazepan-1'-yl)-10H-benzo[b]thieno[2,3-e] [1,4]diazepine), for their tendency to induce weight gain in rats. Weight gain and metabolic changes were measured in female Sprague Dawley rats. Animals were treated orally with Olz, OlzEt, OlzHomo (3 or 6 mg/kg/day), or vehicle (n = 8), three times daily at eight-hour intervals for 5 weeks. Furthermore, a phencyclidine (PCP)-treated rat model was used to examine the prevention of PCP-induced hyperlocomotor activity relevant for schizophrenia therapy. Male Sprague Dawley rats were pre-treated with a single dose (3 mg/kg/day) of Olz, OlzEt, OlzHomo, or vehicle (n = 12), for 2 weeks. Locomotor activity was recorded following a subcutaneous injection with either saline or PCP (10 mg/kg). Olz was found to induce weight gain, hyperphagia, visceral fat accumulation, and metabolic changes associated with reduced histamatergic H1 receptor density in the hypothalamus of treated rats. In contrast, OlzEt and OlzHomo presented promising antipsychotic effects, which did not induce weight gain or fat deposition in the treated animals. Behavioural analysis showed OlzEt to attenuate PCP-induced hyperactivity to a level similar to that of Olz; however, OlzHomo showed a lower propensity to inhibit these stereotyped behaviours. Our data suggest that the therapeutic effectiveness of OlzHomo may be delivered at a higher dose than that of Olz and OlzEt. Overall, OlzEt and OlzHomo may offer a better pharmacological profile than Olz for treating patients with schizophrenia. Clinical trials are needed to test this hypothesis.
- Published
- 2013
- Full Text
- View/download PDF
35. Association between DBH 19 bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients.
- Author
-
Hui L, Zhang X, Yu YQ, Han M, Huang XF, Chen DC, Wang ZR, Du WL, Kou CG, Yu Q, Kosten TR, and Zhang XY
- Subjects
- Adolescent, Adult, Base Sequence genetics, Female, Gene Frequency, Genetic Association Studies, Genotype, Humans, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Statistics, Nonparametric, Young Adult, Cognition Disorders etiology, Dopamine beta-Hydroxylase genetics, Genetic Predisposition to Disease genetics, Mutagenesis, Insertional genetics, Schizophrenia complications, Schizophrenia genetics, Sequence Deletion genetics
- Abstract
Many genes associated with dopamine (DA) and norepinephrine (NE) systems influence cognitive deficits of schizophrenia patients, but one key enzyme is dopamine beta-hydroxylase (DBH), which converts DA to NE and whose activity and levels are under strong genetic control. This study examines the association of the 19 bp insertion/deletion (Ins/Del) polymorphism in the 5' flank of the DBH gene with cognitive deficits in first-episode schizophrenic patients (FEP). We assessed the cognitive function in 195 FEP and 304 healthy controls using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The 19 bp Ins/Del polymorphism of DBH gene was genotyped. Our results showed that the allelic and genotypic frequencies of the 19 bp Ins/Del polymorphism significantly differed between FEP and healthy controls (both p < 0.05). Cognitive test scores were significantly lower in FEP than healthy controls on all scales (all p < 0.001) except for the visuospatial/constructional index (p > 0.05). Immediate memory abilities significantly differed by genotype (p<0.05) but not genotype×diagnosis. Immediate memory score was lower in FEP with DBH5'-Del/Del genotype (61.3 ± 17.2) than those with DBH5'-Ins/Ins genotype (68.6 ± 16.2; p < 0.05). The 19 bp Del allele was associated with poorer immediate memory performance than the Ins allele in FEP (p < 0.05). However, healthy controls did not show any differences in cognitive function indices between the Ins and Del for either the allele or genotype of the 19 bp Ins/Del polymorphism. Our findings suggest that the DBH5'-Ins/Del polymorphism may play a role in susceptibility to FEP. The DBH5'-Ins/Del polymorphism may also influence immediate memory in FEP. Moreover, FEP had poorer cognitive function than healthy controls in all examined cognitive domains except for the visuospatial/constructional index., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
36. Diabetes and cognitive deficits in chronic schizophrenia: a case-control study.
- Author
-
Han M, Huang XF, Chen DC, Xiu M, Kosten TR, and Zhang XY
- Subjects
- Antipsychotic Agents therapeutic use, Attention, Case-Control Studies, Cognition, Cognition Disorders etiology, Cognition Disorders psychology, Cross-Sectional Studies, Diabetes Mellitus, Type 2 complications, Female, Humans, Male, Memory, Short-Term, Middle Aged, Schizophrenia drug therapy, Cognition Disorders diagnosis, Diabetes Mellitus, Type 2 psychology, Schizophrenia complications, Schizophrenic Psychology
- Abstract
Cognitive impairment occurs in both schizophrenia and diabetes. There is currently limited understanding whether schizophrenia with diabetes has more serious cognitive deficits than schizophrenia without diabetes or diabetes only. This study assessed cognitive performance in 190 healthy controls, 106 diabetes only, 127 schizophrenia without diabetes and 55 schizophrenia with diabetes. This study was conducted from January 2008 to December 2010. Compared to healthy controls, all patient groups had significantly decreased total and five index RBANS scores (all p<0.01-p<0.001), except for the visuospatial/constructional index. Schizophrenia with diabetes performed worse than schizophrenia without diabetes in immediate memory (p<0.01) and total RBANS scores (<0.05), and showed a trend for decreased attention (p = 0.052) and visuospatial/constructional capacity (p = 0.063). Schizophrenia with diabetes performed worse than diabetes only in immediate memory (p<0.001) and attention (p<0.05), and showed a trend for decreased total RBANS scores (p = 0.069). Regression analysis showed that the RBANS had modest correlations with schizophrenia' PANSS scores, their duration of current antipsychotic treatment, and diagnosis of diabetes. Schizophrenia with co-morbid diabetes showed more cognitive impairment than schizophrenia without diabetes and diabetes only, especially in immediate memory and attention.
- Published
- 2013
- Full Text
- View/download PDF
37. Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment.
- Author
-
Matosin N, Frank E, Deng C, Huang XF, and Newell KA
- Subjects
- Adolescent, Adult, Aged, Analysis of Variance, Animals, Antipsychotic Agents therapeutic use, Excitatory Amino Acid Antagonists pharmacokinetics, Female, Functional Laterality, Humans, Male, Middle Aged, Postmortem Changes, Protein Binding drug effects, Pyridines pharmacokinetics, Radioligand Assay, Rats, Rats, Sprague-Dawley, Receptor, Metabotropic Glutamate 5, Schizophrenia drug therapy, Time Factors, Tritium pharmacokinetics, Young Adult, Antipsychotic Agents pharmacology, Receptors, Metabotropic Glutamate metabolism, Schizophrenia pathology
- Abstract
Metabotropic glutamate receptor 5 (mGluR5) has been identified as a potential therapeutic target for schizophrenia, primarily due to its ability to indirectly modulate glutamatergic signalling through the NMDA receptor (NMDAR). Despite its potential, molecular studies characterising mGluR5 in schizophrenia are limited. We therefore aimed to determine if the mGluR5 binding site or protein levels were altered in schizophrenia or by current antipsychotics. Using in-situ radioligand binding and immunoblot, we measured [(3)H]MPEP binding to mGluR5 and mGluR5 protein density in the post-mortem dorsolateral prefrontal cortex (DLPFC; BA46) of 37 schizophrenia and 37 matched control subjects. Subsequently, we measured [(3)H]MPEP binding in rat brains following typical (haloperidol) or atypical (olanzapine) antipsychotic treatment (n = 6/group). Subjects with schizophrenia showed no significant alteration in mGluR5 binding density or mGluR5 protein levels. Furthermore, mGluR5 binding in the rat cortex, thalamus, hippocampus and striatum was unaltered by short-, medium- and long-term antipsychotic treatment. Our data suggests that there are no alterations in mGluR5 in schizophrenia subjects. The lack of alteration in mGluR5 binding and protein in schizophrenia is advantageous because its ability to modulate the NMDAR is potentially unhindered, thereby supporting the development of novel antipsychotic agents that work through the mGluR5/NMDAR complex., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
38. Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.
- Author
-
Deng C, Pan B, Engel M, and Huang XF
- Subjects
- Animals, Animals, Genetically Modified, Dopaminergic Neurons metabolism, ErbB Receptors genetics, Humans, Neuregulins genetics, Neuregulins metabolism, Prefrontal Cortex metabolism, RNA, Messenger biosynthesis, Receptor, ErbB-4, Receptors, Glutamate metabolism, Schizophrenia genetics, Signal Transduction physiology, Antipsychotic Agents pharmacology, ErbB Receptors metabolism, Neuregulin-1 metabolism, Schizophrenia physiopathology
- Abstract
Identifying the signalling pathways underlying the pathophysiology of schizophrenia is an essential step in the rational development of new antipsychotic drugs for this devastating disease. Evidence from genetic, transgenic and post-mortem studies have strongly supported neuregulin-1 (NRG1)-ErbB4 signalling as a schizophrenia susceptibility pathway. NRG1-ErbB4 signalling plays crucial roles in regulating neurodevelopment and neurotransmission, with implications for the pathophysiology of schizophrenia. Post-mortem studies have demonstrated altered NRG1-ErbB4 signalling in the brain of schizophrenia patients. Antipsychotic drugs have different effects on NRG1-ErbB4 signalling depending on treatment duration. Abnormal behaviours relevant to certain features of schizophrenia are displayed in NRG1/ErbB4 knockout mice or those with NRG1/ErbB4 over-expression, some of these abnormalities can be improved by antipsychotic treatment. NRG1-ErbB4 signalling has extensive interactions with the GABAergic, glutamatergic and dopaminergic neurotransmission systems that are involved in the pathophysiology of schizophrenia. These interactions provide a number of targets for the development of new antipsychotic drugs. Furthermore, the key interaction points between NRG1-ErbB4 signalling and other schizophrenia susceptibility genes may also potentially provide specific targets for new antipsychotic drugs. In general, identification of these targets in NRG1-ErbB4 signalling and interacting pathways will provide unique opportunities for the development of new generation antipsychotics with specific efficacy and fewer side effects.
- Published
- 2013
- Full Text
- View/download PDF
39. Gender differences in cognitive function of patients with chronic schizophrenia.
- Author
-
Han M, Huang XF, Chen DC, Xiu MH, Hui L, Liu H, Kosten TR, and Zhang XY
- Subjects
- Case-Control Studies, Chronic Disease, Cognition Disorders complications, Female, Humans, Male, Memory, Short-Term, Middle Aged, Neuropsychological Tests statistics & numerical data, Psychiatric Status Rating Scales statistics & numerical data, Repression, Psychology, Schizophrenia complications, Cognition Disorders psychology, Schizophrenia diagnosis, Schizophrenic Psychology, Sex Characteristics
- Abstract
Schizophrenic patients have cognitive impairments, but gender differences in these cognitive deficits have had limited study. This study assessed cognitive functioning in 471 subjects including 122 male and 78 female schizophrenic patients and 141 male and 130 female healthy controls. We found that immediate memory, language, delayed memory and total RBANS scores were significantly decreased in schizophrenia compared with healthy controls for both genders. Male patients had significant lower immediate memory, delayed memory and total RBANS scores than female patients, and healthy controls showed a similar gender difference. The RBANS showed modest correlations with PANSS scores, duration of illness and antipsychotic dose (chlorpromazine equivalents). Almost all RBANS scores in the schizophrenics and healthy controls showed significant positive correlations with education. Thus, patients of both sexes with schizophrenia experienced more deteriorated performance than healthy controls on cognitive domains of immediate memory, language and delayed memory. Furthermore, male schizophrenic patients had more serious cognitive deficits than female patients in immediate and delayed memory, but not in language, visuospatial and attention indices., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
40. The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia.
- Author
-
Hui L, Zhang X, Huang XF, Han M, Fernandez F, Yu Y, Sun S, Li W, Chen DC, Xiu MH, Kosten TR, and Zhang XY
- Subjects
- Adolescent, Adult, Age Factors, Antipsychotic Agents therapeutic use, Case-Control Studies, Female, Gene Frequency, Genotype, Humans, Logistic Models, Male, Middle Aged, Psychiatric Status Rating Scales, Schizophrenia drug therapy, Young Adult, Dopamine beta-Hydroxylase genetics, Genetic Predisposition to Disease, Polymorphism, Genetic genetics, Schizophrenia genetics, Sequence Deletion genetics
- Abstract
Background: Numerous studies report dysfunctional dopaminergic and noradrenergic neurotransmission in the pathogenesis of schizophrenia. Dopamine beta-hydroxylase (DBH) is an intracellular enzyme catalyzing the conversion of dopamine to noradrenaline. Functional polymorphisms have been reported in the promoter region of DBH gene, including a 19 bp insertion/deletion polymorphism. The purpose of this study was to investigate whether there was an association between the functional polymorphism (DBH5'-Ins/Del) and schizophrenia in a Han Chinese population., Methods: This polymorphism was genotyped in 221 first-episode schizophrenics, 360 chronic schizophrenics and 318 healthy controls using a case-control design. We assessed their psychopathology using the Positive and Negative Syndrome Scale (PANSS)., Results: We showed that the DBH5'-Ins/Del deletion (Del) allelic and genotypic frequencies were significantly lower in controls than first-episode of schizophrenics (FES) (both p < 0.001), but controls were not different from chronic schizophrenics. Furthermore, the PANSS positive symptom and total scores were significantly higher in FES with the Del/Del genotype than those with Ins/Del and Ins/Ins genotypes (all p < 0.05)., Conclusions: The DBH5'-Ins/Del polymorphism may play a role in susceptibility to the positive symptoms of FES and to these FES not progressing on to chronic schizophrenia., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
41. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.
- Author
-
Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, Zhang XL, Huang GS, Qu SC, Bai JS, Huang XF, Kosten TR, and Zhang XY
- Subjects
- Adult, Aged, Antipsychotic Agents administration & dosage, Antipsychotic Agents therapeutic use, Chronic Disease, Cross-Sectional Studies, Electrocardiography, Female, Hospitals, Psychiatric, Humans, Institutionalization, Long QT Syndrome chemically induced, Long QT Syndrome epidemiology, Male, Middle Aged, Prevalence, Regression Analysis, Schizophrenia complications, Schizophrenia epidemiology, Time Factors, Antipsychotic Agents adverse effects, Long QT Syndrome etiology, Schizophrenia drug therapy, Sex Characteristics
- Abstract
Objective: The rate-corrected electrocardiographic QT (QTc) interval may significantly increase in patients with schizophrenia taking antipsychotics. The objective of this naturalistic study was to assess the prevalence of prolonged QTc interval in a large population of inpatients with chronic schizophrenia and to explore QTc relationship with demographic variables and prescribed treatments., Materials and Methods: Electrocardiograms were obtained from age- and sex-matched 456 controls and 1,006 inpatients with schizophrenia (male/female = 689/317) taking antipsychotics. QTc prolongation was defined as a mean value of two standard deviations above the controls. The adjusted relative risk was calculated using logistic regression analysis., Results: QTc prolongation was present in 45 (4.5%) of 1,006 patients overall. Fewer men (3.2%, 22 of 689) than women (7.3%, 23 of 317) displayed QTc prolongation (p < 0.004). Moreover, QTc intervals were shorter in male (391 ± 31 ms) than female subjects (400 ± 37 ms) (p < 0.001). Clozapine was found to produce a longer QTc intervals compared to risperidone and typical antipsychotics. Furthermore, multiple regression analysis showed that significant predictors for QTc prolongation were comorbid cardiovascular disease, antipsychotic types, sex, and age (all p < 0.01)., Conclusion: Our present findings suggest that there are sex differences in the prevalence of QTc prolongation and QTc lengthening in schizophrenia. Antipsychotic types are risk factors for QTc prolongation, and risks are substantially higher for clozapine.
- Published
- 2011
- Full Text
- View/download PDF
42. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.
- Author
-
Geddes AE, Huang XF, and Newell KA
- Subjects
- ErbB Receptors physiology, Gene Expression Regulation physiology, Humans, Neuregulin-1 biosynthesis, Neuregulin-1 genetics, Receptor, ErbB-4, Receptors, N-Methyl-D-Aspartate biosynthesis, Receptors, N-Methyl-D-Aspartate genetics, Schizophrenia genetics, Neuregulin-1 physiology, Receptors, N-Methyl-D-Aspartate physiology, Schizophrenia physiopathology, Signal Transduction physiology
- Abstract
Schizophrenia is a debilitating neurodevelopmental psychiatric disorder. Both the N-methyl-D-aspartate receptor (NMDAR) and neuregulin1 (NRG1) are key molecules involved in normal brain development that have been linked to schizophrenia pathology and aetiology. The NR2 proteins are critical structural and functional subunits of the NMDAR and are developmentally and spatially regulated. Altered NR2 gene and protein expression has been found in human post-mortem schizophrenia brain tissue together with changes in NRG1 and its receptor ErbB4. The NR2 subunits and ErbB4 share a common anchoring domain on the postsynaptic density and therefore a disruption to either of these molecules may influence the functioning of the other. It has been shown that NRG1 signalling can affect NMDAR levels and function, particularly phosphorylation of the NR2 subunits. However little is known about the possible effects of NMDAR dysfunction on NRG1 signalling, which is important with regards to schizophrenia aetiology as numerous risk factors for the disorder can alter NMDAR functioning during early brain development. This review focuses on the role of the NMDA receptor subunits and NRG1 signalling in schizophrenia and proposes a mechanism by which a disruption to the NMDAR, particularly via altering the balance of NR2 subunits during early development, could influence NRG1 signalling., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
43. Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.
- Author
-
Pan B, Huang XF, and Deng C
- Subjects
- Animals, Antipsychotic Agents adverse effects, Behavior, Animal drug effects, ErbB Receptors genetics, Humans, Isomerism, Neuregulin-1 genetics, Receptor, ErbB-4, Receptors, G-Protein-Coupled physiology, Antipsychotic Agents pharmacology, ErbB Receptors physiology, Neuregulin-1 physiology, Schizophrenia drug therapy, Signal Transduction drug effects
- Abstract
Evidence from genetic, transgenic and post-mortem studies has strongly supported the critical role that neuregulin 1 (NRG1) and its ErbB4 receptor plays in the pathophysiology of schizophrenia. This article aims to review current evidence regarding the effects of antipsychotic treatment on NRG1-ErbB4 signalling. NRG1 and ErbB4 knockout mice display abnormal behaviours relevant to certain features of schizophrenia, which could be improved by antipsychotic (clozapine/haloperidol) treatment. In contrast to most NRG1/ErbB4 knockout mice with a decreased NRG1-ErbB4 signalling, the majority post-mortem studies showed an increased NRG1-ErbB4 signalling in schizophrenic patients. These differences could be due to degrees of alteration in risk genes (subtle variations in patients vs pronounced alteration in mutant mice) or the duration of the modification on NRG1 signalling. Various antipsychotics have different effects on NRG1 and ErbB4 expression and signalling that are dependent on treatment duration. Current evidence suggests that a chronic (12weeks) antipsychotic treatment, at least in animal models, could downregulate NRG1-ErbB4 signalling, although an upregulation is seen for a short-term treatment. These effects may be due to multiple binding profiles with various G-coupled protein receptors (e.g. dopamine, and serotonin receptors) of antipsychotics. Studies are needed to investigate the interactions between NRG1-ErbB4 and the other signalling pathways (such as glutamatergic, GABAergic and dopaminergic). Furthermore, the interactions between NRG1/ErbB4 and other schizophrenia suspensibility genes under antipsychotic treatment also require investigation., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
44. Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age.
- Author
-
Frank E, Newell KA, and Huang XF
- Subjects
- Adolescent, Adult, Aged, Aging pathology, Bridged Bicyclo Compounds pharmacokinetics, Excitatory Amino Acid Agonists pharmacokinetics, Female, Humans, Male, Middle Aged, Postmortem Changes, Prefrontal Cortex drug effects, Protein Binding drug effects, Radiography, Radioligand Assay, Statistics as Topic, Tritium, Young Adult, Aging metabolism, Prefrontal Cortex diagnostic imaging, Receptors, Metabotropic Glutamate metabolism, Schizophrenia pathology
- Abstract
Metabotropic glutamate receptors 2 and 3 (mGluR2/3) have been shown as efficient targets for antipsychotic intervention. We therefore investigated the receptor density of mGluR2/3 in the dorsolateral prefrontal cortex (dlPFC; Brodman area 46) of schizophrenia/schizoaffective patients (n=37) and matched controls (n=37) using receptor autoradiography. No difference in mGluR2/3 density was identified in relation to schizophrenia diagnosis. Overall and in individual groups, a negative correlation of mGluR2/3 density and age at death has been found. These and previous results suggest that density of mGluR2/3 in the dlPFC is less likely to impact on the efficiency of the mGluR2/3 agonist in treating schizophrenia symptoms., (Crown Copyright © 2011. Published by Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
45. Potential control of risperidone-related cognitive deficits by adjunctive aripiprazole treatment.
- Author
-
Hu CH, Pai N, Huang XF, and Deng C
- Subjects
- Female, Humans, Male, Radionuclide Imaging, Attention Deficit Disorder with Hyperactivity diagnostic imaging, Dopamine Antagonists therapeutic use, Dopamine D2 Receptor Antagonists, Risperidone therapeutic use, Schizophrenia diagnostic imaging, Schizophrenia drug therapy
- Published
- 2011
- Full Text
- View/download PDF
46. Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
- Author
-
Lian J, Huang XF, Pai N, and Deng C
- Subjects
- Adolescent, Antipsychotic Agents adverse effects, Aripiprazole, Child, Humans, Antipsychotic Agents therapeutic use, Bipolar Disorder drug therapy, Hyperprolactinemia chemically induced, Obesity chemically induced, Piperazines therapeutic use, Quinolones therapeutic use, Schizophrenia drug therapy
- Published
- 2010
- Full Text
- View/download PDF
47. The PI3K/Akt pathway may play a key role in social isolation-caused schizophrenia comment re: Increased dopamine D2(High) receptors in rats reared in social isolation.
- Author
-
Chen J and Huang XF
- Subjects
- Animals, Brain physiopathology, Cell Differentiation physiology, Disease Models, Animal, Dopamine metabolism, Enzyme Activation physiology, Neurogenesis physiology, Rats, Schizophrenia etiology, Schizophrenia physiopathology, Signal Transduction physiology, Brain metabolism, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, Receptors, Dopamine D2 metabolism, Schizophrenia metabolism, Social Isolation psychology
- Published
- 2010
- Full Text
- View/download PDF
48. Neuregulin 1, brain region specificity and PI3K/Akt in schizophrenia: comment on "Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal area".
- Author
-
Huang XF and Chen J
- Subjects
- Frontal Lobe metabolism, Humans, Schizophrenia genetics, Schizophrenia metabolism, Signal Transduction, Temporal Lobe metabolism, Frontal Lobe physiopathology, Neuregulin-1 genetics, Phosphatidylinositol 3-Kinases metabolism, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-akt metabolism, Schizophrenia physiopathology, Temporal Lobe physiopathology
- Published
- 2009
- Full Text
- View/download PDF
49. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia--a postmortem study.
- Author
-
Kang K, Huang XF, Wang Q, and Deng C
- Subjects
- Adolescent, Adult, Aged, Hallucinations metabolism, Hallucinations physiopathology, Humans, Male, Middle Aged, Protein Binding physiology, Temporal Lobe physiopathology, Receptor, Serotonin, 5-HT2A metabolism, Schizophrenia metabolism, Schizophrenia physiopathology, Serotonin 5-HT2 Receptor Antagonists, Temporal Lobe chemistry, Temporal Lobe metabolism
- Abstract
The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of schizophrenia, particularly with regards to auditory hallucinations. In this study, using in situ quantitative autoradiography in postmortem tissue, we investigated the binding of the [3H]ketanserin to 5-HT(2A) receptors and [3H]mesulergine to 5-HT(2C) receptors in the left STG of 8 male schizophrenic patients compared to 8 control subjects. A strong [3H]ketanserin binding was observed in the STG, however there was a very weak [3H]mesulergine binding in the STG. A significant decrease in binding of [(3)H]ketanserin was clearly observed in schizophrenia patients in comparison with control subjects. There were no significant correlations between 5-HT(2A) binding density and age, postmortem intervals, or brain pH. These results suggest that the alterations of the 5-HT(2A) receptors contribute to the pathophysiology of the STG in schizophrenia. Furthermore, there is a clear tendency for a positive correlation between 5-HT(2A) and muscarinic M1 receptor bindings, and for negative correlations between 5-HT(2A) and GABA(A) receptor bindings and between muscarinic M1 and GABA(A) receptor bindings. This provides a possible mechanism of auditory hallucinations through interactions between 5-HT(2A), acetylcholine muscarinic and GABA transmissions in the STG in schizophrenia.
- Published
- 2009
- Full Text
- View/download PDF
50. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.
- Author
-
Deng C, Han M, and Huang XF
- Subjects
- Adult, Aged, Autoradiography, Case-Control Studies, Humans, Middle Aged, Receptor, Cannabinoid, CB1 agonists, Receptor, Cannabinoid, CB1 antagonists & inhibitors, Reference Values, Schizophrenia physiopathology, Receptor, Cannabinoid, CB1 metabolism, Schizophrenia metabolism, Temporal Lobe metabolism
- Abstract
Objective: In recent years, abnormal changes in the endocannabinoid system have been found in schizophrenia. The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of schizophrenia, particularly with regards to auditory hallucinations. In this study, we investigated the binding density of cannabinoid CB1 receptors in the STG of schizophrenia patients compared to control subjects., Methods: Quantitative autoradiography was used to investigate the binding densities of [(3)H]SR141716A (a selective antagonist) and [(3)H]CP-55940 (an agonist) to the CB1 receptors in the STG. Post-mortem brain tissue was obtained from the NSW Tissue Resource Centre (Australia)., Results: Contrasting to previous findings in the alterations of CB1 receptor densities in the prefrontal, anterior and posterior cingulate cortex of schizophrenia, which were suggested to be associated to impairment of cognition function, no significant difference was found between the schizophrenia and control cases in both [(3)H]SR141716A and [(3)H]CP-55940 binding., Conclusion: We suggest that CB1 receptors in the STG are not involved in the pathology of schizophrenia and the auditory hallucination symptom of this disease.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.